1

Promising Advancements in Gene Therapy are Leading to Potential Investment Opportunities

Today’s discussion is about a topic that fascinates me even though I can say that I do not fully understand it, and that is gene therapy. I am not talking about the self-serving gene editing done in vitro in an attempt to ensure your child has blue eyes and a greater likelihood of being the smartest kid in class. Although I am sure it would make a great ethical debate as to where one draws the line on this subject. What I am talking about is the development of gene therapies in an attempt to limit or even cure diseases.

Advances in gene therapies

Advances in this field have been nothing short of miraculous over the last 20 years, since the completion of the Human Genome Project (“HGP”) in 2003. As a refresher, the goal of this international project was to determine the base pairs that make up human DNA (“Deoxyribonucleic acid”), and to identify, map, and sequence all the genes of the human genome from both a physical and a functional standpoint.

With that said, the project was not able to sequence all of the DNA found in human cells, simply specific regions of the nuclear genome, which make up 92% of the human genome. It was not until 2022 that the complete sequencing of all 24 human chromosomes was completed and even that is up for debate.

The Human Genome Project

Why was the completion of the HGP such a big deal? The sequencing of the human genome can hold many benefits including ways to identify the genetic variants that increase the risk for common diseases like cancer and diabetes. It can help researchers understand diseases including:

  • Genotyping of specific viruses for direct treatment;
  • Identification of mutations linked to different forms of cancer;
  • The design of medication and more accurate prediction of their effects; and,
  • Even the evolution of diseases.

Plus, you can now find out if you have some long-lost relatives anywhere in the world by simply putting some spit in the mail. But again, I digress.

FDA to accelerate the approval of gene therapies

The big news in this field came out last week from none other than the U.S. Food and Drug Administration (“FDA”). Agency official Peter Marks (head of the FDA’s Center for Biologics Evaluation and Research) stated that the FDA needs to start accelerating approvals for advancing gene therapies for rare diseases. Taking a page from the common sense manual, as opposed to the big book of bureaucracy, he suggested this would be particularly important for ultra-rare diseases, for which there are too few patients to run placebo-controlled studies. According to the report Marks said, “When you’re making a gene therapy for 10, 20 people a year, the concept that you’re going to do a randomized clinical trial falls apart pretty quickly.” Sounds pretty logical to me, but sadly there seems to be a shortfall in logic in a lot of policies these days.

Potentially good timing for investment opportunities

This sounds like the makings of a potentially good investment opportunity, over and above the possible benefits to society as a whole. But here’s where I’m not sure I can be a lot of help. As I noted above, gene therapy fascinates me but I do not know enough about the science to pick a winner versus a wannabe. So instead I will simply present one company in this field that has a story that I find interesting (even though they have a terrible-looking chart). Think of this as an example of what could be with this technology and what it could potentially do for humankind.

The company is Taysha Gene Therapies, Inc. (NASDAQ: TSHA), a clinical-stage gene therapy company focused on developing and commercializing adeno-associated virus (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system (“CNS”). One of the treatments they are developing (TSHA-102) is a gene transfer therapy for Rett syndrome, a rare inherited genetic neurodevelopmental disorder. The Company is on track to dose the first patient and deliver first-in-human adult data for TSHA-102 in the first half of 2023. Without getting into the details of what Rett Syndrome is, or the administration and composition of TSHA-102 (which there is no hope in hell I could pull off), I think it is amazing that in a matter of months, we could be getting feedback on whether this treatment is showing signs of being successful or not.

Final thoughts

As I noted at the beginning, there are probably a lot of people out there debating how far we can ethically take gene therapy, and for good reason. However, if politicians and scientists can stay focused on the “greater good”, perhaps we could start to see people with these rare and ultra-rare diseases actually have some hope. And if gene therapy advances enough to start curing the likes of cancer and diabetes then I suggest we hold a parade and a giant party for anyone and everyone involved.

Taysha Gene Therapies – 1-Year Stock Chart

Source: S&P Capital IQ



Thomas Smeenk on Hemostemix products for Your Fountain of Youth

In a recent InvestorIntel interview, Tracy Weslosky spoke with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF) about Hemostemix’s recent “blockbuster” news release on collaborating with world famous Dr. James Shapiro to Treat Type 1 Diabetes and about trademarking “Your Fountain of Youth”.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Thomas Smeenk said that Dr. James Shapiro is well known and respected for creating the Edmonton Protocol for the treatment of  Type 1 Diabetes. Thomas went on to provide an update on Hemostemix’s technology platform that uses stem cells from a patient’s own blood to treat the heart-damage following a heart attack. Providing an update on Hemostemix’s recently closed oversubscribed private placement, he went on to explain how Hemostemix has found a “Fountain of Youth.”

To watch the full interview, click here.

About Hemostemix Inc.

Hemostemix is a publicly traded autologous (utilizing the patient’s own stem cells) stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and has published seven peer reviewed articles about the safety and efficacy of its lead product ACP-01 as a treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up” which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.

The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy.

To learn more about Hemostemix Inc., click here.

Disclaimer: Hemostemix Inc. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].